FDA Issues OAI for Key Drug Facility, Achieve Life Sciences Expects CRL and Q4 Resubmission
Summary
Achieve Life Sciences announced that the FDA issued an Official Action Indicated (OAI) classification for its third-party manufacturing facility, which will lead to a Complete Response Letter (CRL) for its cytisinicline New Drug Application (NDA) by June 20, 2026. This confirms the "potential FDA approval delays" mentioned in the company's recent 10-K. In response, Achieve has completed the technology transfer of cytisinicline manufacturing to Adare Pharma Solutions and plans to resubmit the NDA with Adare as the manufacturer in Q4 2026. The OAI and expected CRL represent a significant regulatory setback for Achieve's primary product candidate, cytisinicline, pushing back the potential approval and commercial launch timeline. While the manufacturing transfer to Adare is a necessary mitigation, it does not negate the immediate delay. For a small-cap company with a 'going concern' warning, any delay in its key product's path to market is material. Investors will monitor the receipt of the CRL, the specifics of the FDA's requirements, and the progress of the NDA resubmission with Adare in Q4 2026, as well as any potential impact on the reiterated H1 2027 launch target.
At the time of this announcement, ACHV was trading at $3.67 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $192.2M. The 52-week trading range was $1.95 to $6.03. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.